Project Grant R01CA316658
- The National Cancer Institute awarded The Leland Stanford Junior University $661,135 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support basic and applied research on rewiring oncogenic pathways to induce cell death in chronic lymphocytic leukemia. The funded work, led by investigators Crabtree, Kay, Gray, and Woyach, develops a new class of small molecules called TCIPs (transcriptional/epigenetic chemical inducers of proximity) designed to activate programmed...
- The National Cancer Institute awarded The Leland Stanford Junior University $137,266 on July 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop comprehensive profiling methods for T-cell lymphomas and personalized therapeutic interventions. The project encompasses three research aims. Aim 1 develops disease monitoring and clonal evolution assessment in T-cell lymphoma by integrating targeted sequencing of cell-free DNA to detect circulating tumor DNA, viral genomes,...
- The National Cancer Institute awarded The Leland Stanford Junior University $644,703 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394, Assistance Listing) to develop a human bone marrow organoid culture method that sustains both normal and leukemic hematopoiesis. The project addresses a historic inability to culture hematopoietic stem cells, progenitors, and leukemic blasts beyond days to weeks by recapitulating the structurally and cellularly complex...
- The National Cancer Institute awarded The Leland Stanford Junior University $143,278 under the Cancer Research Manpower program (CFDA 93.398) on January 1, 2026, to support research investigating evolutionary antagonism between tumors and lymphocytes. The recipient will conduct analyses of clonal diversity in metastatic cancer cells using viral integration site mapping across nine rounds of in vivo selection, perform single-cell transcriptomics to profile phenotypic diversity in relation to...
- The National Institutes of Health National Cancer Institute awarded The Leland Stanford Junior University $638,972 on August 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an integrated liquid biopsy framework for noninvasive characterization of peripheral T-cell lymphomas. The funded research integrates circulating cell-free DNA and cell-free RNA analysis to detect minimal residual disease, monitor disease dynamics, improve disease classification,...
- The National Cancer Institute awarded a $1.21 million cooperative agreement to The Leland Stanford Junior University on August 7, 2026, to support research on tumor-immune coevolution during metastatic progression under the Cancer Biology Research program (CFDA 93.396). The research investigates how tumors and lymphocytes undergo reciprocal adaptive evolution throughout metastasis, with focus on mechanisms by which early-stage metastatic tumors exploit immune education within lymph nodes to...
- The National Cancer Institute awarded The Leland Stanford Junior University $593,557 on March 18, 2026, under CFDA 93.394 (Cancer Detection and Diagnosis Research) to develop magnetic resonance methods for measuring response to an emerging lipophilic cancer therapy, specifically BPM31510, a coenzyme Q10 lipid nanoemulsion formulation. The research addresses a critical gap in clinical translation: the lack of real-time measurement tools to assess tumor response to this therapeutic agent, which...
- Federal Grant Award Summary The National Cancer Institute awarded The Leland Stanford Junior University a $368,294 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for the period September 1, 2025 through August 31, 2028. This award supports the development of next-generation platforms for interrogating T cell receptor (TCR) specificity to identify and detect tumor antigens at the protein level. The project addresses a critical bottleneck in cancer...
- The National Cancer Institute, within the Department of Health and Human Services, awarded The Leland Stanford Junior University $606,756 on August 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award funds development and validation of foundation model-augmented artificial intelligence tools to enable accurate and efficient image guidance in upright proton therapy for lung cancer treatment. The research will create a vision-language framework for...
- The National Cancer Institute awarded The Leland Stanford Junior University $163,999 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop cost-effective, user-friendly, and high-throughput microfluidic organ-on-a-chip models that recreate the human bone marrow and bone microenvironments to study breast cancer metastasis to bone. The research will investigate how bone-forming osteoblasts and bone endothelial cells facilitate the extravasation and early...
The National Cancer Institute awarded The Leland Stanford Junior University $676,748 under the Cancer Biology Research program (CFDA 93.396) on August 3, 2026, to investigate metabolic drivers of V(D)J diversity in B-cell acute lymphoblastic leukemia and their implications for minimal residual disease detection and relapse prevention. The recipient will conduct three integrated research aims. Aim 1 analyzes high-throughput sequencing immunoglobulin heavy chain data from more than 1,700 patients treated on Phase 3 clinical trials and with standard-of-care immunotherapies to establish the prevalence of V(D)J diversity, its relationship to clinical and molecular features, and its prognostic impact on outcomes. Aim 2 identifies relapse-permissive cellular states through multimodal single-cell profiling of V(D)J rearrangements. Aim 3 targets the metabolic underpinnings of V(D)J-diverse subclones, which show enrichment for activated mTOR signaling and mitochondrial/pyrimidine metabolism, to eliminate resistant populations and prevent relapse. The project period extends from the award date through July 31, 2031, with work performed at Stanford's Palo Alto, California campus. The funding supports research grounded in preliminary findings demonstrating that V(D)J-diverse subclones limit minimal residual disease detectability by sequencing and correlate with poor outcomes despite undetectable disease, addressing gaps in understanding both the biology of residual leukemia cells and the limitations of current detection methods.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $676.7k | 8/3/26 |